Christensen King & Associates Investment Services Inc. Sells 63 Shares of Eli Lilly and Company (NYSE:LLY)

Christensen King & Associates Investment Services Inc. lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 5.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,152 shares of the company’s stock after selling 63 shares during the period. Christensen King & Associates Investment Services Inc.’s holdings in Eli Lilly and Company were worth $1,021,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. CFM Wealth Partners LLC lifted its stake in Eli Lilly and Company by 72.1% during the first quarter. CFM Wealth Partners LLC now owns 7,840 shares of the company’s stock worth $6,099,000 after purchasing an additional 3,285 shares during the last quarter. Chemistry Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 4.6% during the 1st quarter. Chemistry Wealth Management LLC now owns 550 shares of the company’s stock valued at $428,000 after buying an additional 24 shares in the last quarter. CIC Wealth LLC lifted its position in Eli Lilly and Company by 7.8% in the 1st quarter. CIC Wealth LLC now owns 3,134 shares of the company’s stock worth $2,438,000 after buying an additional 227 shares during the last quarter. Constitution Capital LLC boosted its stake in Eli Lilly and Company by 653.9% in the first quarter. Constitution Capital LLC now owns 3,355 shares of the company’s stock worth $2,610,000 after buying an additional 2,910 shares in the last quarter. Finally, Davis Investment Partners LLC bought a new position in Eli Lilly and Company during the first quarter valued at approximately $636,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.3 %

Eli Lilly and Company stock opened at $909.15 on Wednesday. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The business’s fifty day simple moving average is $921.67 and its two-hundred day simple moving average is $860.45. The company has a market capitalization of $864.06 billion, a price-to-earnings ratio of 133.90, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. As a group, equities analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 16th. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Bank of America raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,002.24.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.